Faeth Therapeutics Inc FTH Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$18.80 down $1.80, 8.74% at close Oct 16
Last close · Previous close $20.60
- Market cap
- At the Oct 16 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$18.80down $1.80, 8.74%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$20.60Oct 15
- Volume595.94KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume443.75KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $7.45 to $42.14; now $18.80
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
FTH beat the S&P 500 in 1 of 6 periods.
| Period | FTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | FTH: down 45.1% S&P 500: up 1.5% | FTH trailed the S&P 500 by 46.6 percentage points Trailed |
| 3M | FTH: down 27.5% S&P 500: up 1.9% | FTH trailed the S&P 500 by 29.4 percentage points Trailed |
| YTD | FTH: up 76.2% S&P 500: up 12.8% | FTH beat the S&P 500 by 63.4 percentage points Beat |
| 1Y | FTH: up 7.0% S&P 500: up 16.8% | FTH trailed the S&P 500 by 9.8 percentage points Trailed |
| Long term | ||
| 3Y | FTH: up 25.2% S&P 500: up 81.5% +7.8% vs +22.0% a year | FTH trailed the S&P 500 by 56.3 percentage points Trailed |
| 5Y | FTH: down 87.7% S&P 500: up 83.1% −34.2% vs +12.9% a year | FTH trailed the S&P 500 by 170.8 percentage points Trailed |
$10,000 invested in FTH 5 years ago (Oct 15, 2021) would be worth about $1,232 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
FTH beat the S&P 500 in 1 of 6 periods.
| Period | FTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | FTH: down 45.1% S&P 500: up 1.2% | FTH trailed the S&P 500 by 46.3 percentage points Trailed |
| 3M | FTH: down 27.5% S&P 500: up 1.7% | FTH trailed the S&P 500 by 29.2 percentage points Trailed |
| YTD | FTH: up 76.2% S&P 500: up 11.9% | FTH beat the S&P 500 by 64.3 percentage points Beat |
| 1Y | FTH: up 7.0% S&P 500: up 15.5% | FTH trailed the S&P 500 by 8.5 percentage points Trailed |
| Long term | ||
| 3Y | FTH: up 25.2% S&P 500: up 75.0% +7.8% vs +20.5% a year | FTH trailed the S&P 500 by 49.8 percentage points Trailed |
| 5Y | FTH: down 87.7% S&P 500: up 71.2% −34.2% vs +11.4% a year | FTH trailed the S&P 500 by 158.9 percentage points Trailed |
$10,000 invested in FTH 5 years ago (Oct 15, 2021) would be worth about $1,232 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
All-time high
$455.00
Closing high on . Now 95.9% below that record.
Split-adjusted daily closes since Feb 4, 2021.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$195.53M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$7.25M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$7.77M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$6.86M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$4.94M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$4.57M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$4.72M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$170.24M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$16.01M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$36.79M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$48.59M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$34.10M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$30.16M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$21.09M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$33.86MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$33.86MLast 12 months
- Capital spending$6.00KLast 12 months
Shareholder returns
- $15.78MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$15.78MLast 12 months
Balance sheet
- $186.44MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$592.00KAs of Jun 30, 2026
- Net cash$185.85MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 19.69As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −1,012.2%Last 12 months
Over the last 12 months, Faeth Therapeutics lost money: its net loss was 1,012.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −175.7%Last 12 months
Over the last 12 months, Faeth Therapeutics’s net loss was 175.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Faeth Therapeutics Inc
Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
FTH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
FTH stock FAQ
What is FTH stock’s price today?
Faeth Therapeutics (FTH) traded at $18.80 at the close on , down $1.80 (8.74%) from the previous close of $20.60. Over the past 52 weeks it has traded between $7.45 and $42.14.
If you invested $1,000 in FTH 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in FTH on would be worth about $123 at the close on , a total return of −87.7%. The same $1,000 would be worth $1,070 if invested one year ago. Past performance doesn’t predict future returns.
Does FTH pay a dividend?
Faeth Therapeutics hasn’t paid a dividend in the last twelve months.
What is FTH’s 52-week high and low?
Over the past 52 weeks FTH has traded as low as $7.45 and as high as $42.14. At $18.80 at the close on , it is 55.4% below that high and 152.3% above the low.
What is FTH’s all-time high?
FTH’s highest closing price was $455.00 on , adjusted for stock splits. At $18.80 at the close on , it is 95.9% below that record.
Has FTH stock ever split?
Yes, once: 1-for-20 on .
How has FTH stock performed?
Including dividends and measured to the close on , FTH has returned +76.2% so far this year and +7.0% over the past year, and −87.7% over five years (−34.2% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Faeth Therapeutics in?
Faeth Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.
What exchange does FTH trade on?
Faeth Therapeutics trades on the Nasdaq under the ticker symbol FTH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.